Preemptive Strategy for Ganciclovir Administration Against Cytomegalovirus in Liver Transplantation Recipients
Open Access
- 1 November 2002
- journal article
- Published by Elsevier in American Journal of Transplantation
- Vol. 2 (10) , 955-958
Abstract
In utilizing a preemptive strategy to minimize the occurrence of symptomatic cytomegalovirus (CMV) infection following liver transplant, only patients with proven CMV activity by direct detection are treated. We applied the following preemptive strategy for CMV infection to 49 sequential liver transplant recipients between 1998 and 2001. Patients were monitored for CMV activity using CMV p65 antigen assay for the first 10 months of the study. Thereafter, we changed the detection method to a quantitative PCR for plasma CMV-DNA. All patients were monitored post transplant, weekly for the first 3 months and then monthly. Only patients with detected CMV activity were treated with ganciclovir. Patients were divided into four groups, based on donor (D) and recipient (R) CMV status. In seven out of 49 patients (14.3%) CMV activity was detected: four in group D+/R-, and three in group D-/R-. Five out of these seven patients had asymptomatic CMV infection. Symptomatic CMV infection developed only in two of these seven patients, to give total rate of 4.1% (2/49). All seven patients developed CMV IgG antibody. 'Transient' CMV replication detected by PCR in five patients in group D+/R+ was not defined as infection. No patients developed organ-invasive CMV disease. The cost of anti-CMV treatment using the preemptive strategy was $1000/patient/1st year. Using preemptive strategy, early detection of CMV infection was achieved, allowing timely treatment. The use of ganciclovir for CMV infection in only 4.3% of the patients should have a positive impact on minimizing the risk of ganciclovir-resistant virus, and should reduce the cost of CMV prevention strategies.Keywords
This publication has 16 references indexed in Scilit:
- Preemptive Use of Oral Ganciclovir to Prevent Cytomegalovirus Infection in Liver Transplant Patients: A Randomized, Placebo‐Controlled TrialThe Journal of Infectious Diseases, 2002
- Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant RecipientsClinical Infectious Diseases, 2001
- Prevention of Cytomegalovirus Disease in Recipients of Solid-Organ TransplantsClinical Infectious Diseases, 2001
- Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplantsThe Lancet, 2000
- Cytomegalovirus (CMV) DNA Load Predicts Relapsing CMV Infection after Solid Organ TransplantationThe Journal of Infectious Diseases, 2000
- New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant RecipientsClinical Microbiology Reviews, 2000
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- CYTOMEGALOVIRUS PROPHYLAXIS WITH ANTIVIRAL AGENTS IN SOLID ORGAN TRANSPLANTATIONTransplantation, 1998
- Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipientsThe Lancet, 1997
- High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver Transplant RecipientsAnnals of Internal Medicine, 1994